Mylan Ireland Ltd patent expiration

1. Miacalcin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5733569 MYLAN IRELAND LTD Galenic compositions comprising calcitonin and their use
Mar, 2015

(9 years ago)

US5759565 MYLAN IRELAND LTD Galenic compositions comprising calcitonin and their use
Mar, 2015

(9 years ago)




Drugs and Companies using CALCITONIN SALMON ingredient

Market Authorisation Date: 17 August, 1995

Treatment: Nasal administration

Dosage: SPRAY, METERED

How can I launch a generic of MIACALCIN before it's drug patent expiration?
More Information on Dosage

MIACALCIN family patents

Family Patents

2. Yupelri patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585879 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US7910608 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US7288657 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Dec, 2025

(1 year, 5 months from now)

US11858898 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(5 years from now)

US10550081 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(5 years from now)

US9765028 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(5 years from now)

US8541451 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Aug, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10343995 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US8053448 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US11247969 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US8273894 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US7550595 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US8034946 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US7491736 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US7521041 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US10106503 MYLAN IRELAND LTD Biphenyl compounds useful as muscarinic receptor antagonists
Mar, 2025

(7 months from now)

US11691948 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(5 years from now)

US11008289 MYLAN IRELAND LTD Crystalline freebase forms of a biphenyl compound
Jul, 2030

(5 years from now)

US11484531 MYLAN IRELAND LTD Methods for treating chronic obstructive pulmonary disease
Oct, 2039

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 09, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: 09 November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION

How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage

YUPELRI family patents

Family Patents